Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glatiramer Acetate Clear all
Completed No phase listed Observational

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906
View directory record Official record
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Not applicable Interventional

Treatment of Multiple Sclerosis With Copaxone and Albuterol

NCT00039988
View directory record Official record
Conditions
Autoimmune Diseases, Multiple Sclerosis
Interventions
Glatiramer acetate, Albuterol, Albuterol placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 4 Interventional Results available

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04878211
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells

NCT01993004
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif®, Copaxone®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 5, 2026, 3:36 PM EDT
Suspended Phase 1 Interventional

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

NCT00541333
View directory record Official record
Conditions
Dry Age Related Macular Degeneration
Interventions
Copaxone Injection
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

NCT04121221
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
GA Depot, Placebo
Drug · Other
Lead sponsor
Mapi Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

NCT05767736
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
10,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 5, 2026, 3:36 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

NCT05688436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Drug · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 3 Interventional Results available

Vitamin D Supplementation in Multiple Sclerosis

NCT01490502
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Vitamin D3
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
16
States / cities
Carmichael, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

NCT03399981
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Tysabri
Biological
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
80,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

NCT01695434
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00451204
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Estriol, Placebo, Copaxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 5, 2026, 3:36 PM EDT
Withdrawn Phase 2 Interventional

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00939549
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Cyclophosphamide/Glatiramer acetate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

NCT02153723
View directory record Official record
Conditions
Rett Syndrome
Interventions
Glatiramer Acetate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
10 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 5, 2026, 3:36 PM EDT
Completed Phase 2 Interventional

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

NCT00202982
View directory record Official record
Conditions
Relapse-Remitting Multiple Sclerosis
Interventions
glatiramer acetate 20 mg, glatiramer acetate 40 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
20
States / cities
La Jolla, California • Oceanside, California • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01578785
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer Acetate, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Cullman, Alabama • Fresno, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 5, 2026, 3:36 PM EDT
Terminated Phase 3 Interventional Results available

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

NCT01633112
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
fingolimod, glatiramer acetate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
101
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 5, 2026, 3:36 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NCT05162638
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
thoracic duct cannulation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 5, 2026, 3:36 PM EDT